OpenResearchAlpha

Hepatology Communications · 20 Nov 2026

High adherence to trientine tetrahydrochloride among U.S. patients with Wilson disease: A nationwide specialty pharmacy analysis

Amanda Cheungh-index 7, Peter Hedera, Amy Brown, Jamie Heise, Omar Kamlin, Veronica Tomor, Nick Manamley, Christina Dockery, Fred Askari

0
Citations
no database records one yet
0
Citations in 2026
so far
7
Leading author's h-index
Amanda Cheung, in QAI's scholar index
23
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • OpenAlex0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Background: Wilson disease (WD) is a rare inherited disorder of copper metabolism requiring lifelong therapy. Medication adherence may be challenging given the dosing complexity, meal-timing requirements, and medication storage demands associated with approved therapies, which may compromise copper control and disease progression. Trientine tetrahydrochloride (TETA-4HCl) is a twice-daily oral copper chelator distributed in the United States through a single-source specialty pharmacy with patient services. This study evaluated medication adherence to TETA-4HCl using specialty pharmacy dispensing data. Methods: We conducted a retrospective observational analysis of de-identified specialty pharmacy dispensing data for patients prescribed TETA-4HCl between May 2023 and December 2024. Medication adherence was assessed using proportion of days covered (PDC) and mean gap days per shipment. Patient demographics, prescriber specialty, prior therapies, and reasons for treatment discontinuation were summarized descriptively. Results: A total of 142 patients were included (55% male; mean age 39 y). Prescriptions were primarily written by hepatologists (64%) and gastroenterologists (23%), and 32% of patients traveled out of state for care. Nearly all patients (98.6%) received prior WD therapy, and 46% received more than one prior treatment. Among 93 patients with ≥180 days of follow-up, mean PDC was 84%, and 74% achieved PDC ≥80%. Among 126 patients and 1682 shipments (mean 13), mean gap days were 2.7. Twenty-four patients (16.9%) discontinued therapy during the study period, four (2.8%) due to adverse events. Conclusion: In this real-world U.S. cohort, adherence to TETA-4HCl dispensed from a single-source specialty pharmacy with a coordinated centralized distribution and patient support model was high. Further studies integrating pharmacy data with clinical, biochemical, and patient-reported outcomes are needed to evaluate long-term disease outcomes.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Amanda Cheung has the highest h-index among the authors (7).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (9)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (23)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 3 more references

A free account opens the rest of the citing papers and references on every paper’s page.

High adherence to trientine tetrahydrochloride among U.S. patients with Wilson disease: A nationwide specialty pharmacy analysis - QAI OpenResearch